3SBio Secures NMPA Approval for Pediatric Thrombopoietin Treatment of ITP
3SBio Inc. (HKG: 1530), a leading biopharmaceutical company based in China, has announced that it...
Bayer Partners with Hologic to Develop Contrast-Enhanced Mammography Solution for Breast Cancer Diagnosis
Bayer (ETR: BAYN), a multinational pharmaceutical and life sciences company headquartered in Germany, has announced...
AbbVie’s Aquipta/Qulipta Shows Promise in Migraine Prevention Trial
AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, last week released interim results from a...
Laekna’s Anti-ActRIIA Antibody LAE102 Clears FDA Hurdle for Obesity Treatment Trial
Sino-American biotech firm Laekna has announced that it has received clinical trial approval from the...
NHSA Reports 2023 Milestones in Basic Medical Insurance Participation and Financials
The National Healthcare Security Administration (NHSA) has published its annual “Healthcare Security Development Statistical Bulletin”...
Sanofi Explores Sale of Amunix Pharmaceuticals as It Shifts Focus to Immunology
Sanofi (NASDAQ: SNY), the France-based pharmaceutical giant, is reportedly in talks with potential buyers for...
AstraZeneca’s Fasenra Gains FDA Approval for Pediatric Severe Asthma Treatment
AstraZeneca (AZ; NASDAQ: AZN) has secured an indication extension from the U.S. Food and Drug...
Qilu Pharmaceutical Gets NMPA Green Light for Generic Romiplostim for ITP Treatment
The National Medical Products Administration (NMPA) in China has granted marketing approval to Qilu Pharmaceutical...
Suzhou Zelgen Receives NMPA Approval for Jacktinib Cream Trial in Vitiligo Patients
Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) has announced that it has received approval from...
Haisco Pharmaceutical Gets NMPA Green Light for HSK31858 COPD Trial
Haisco Pharmaceutical Group Co., Ltd (SHE: 002653), a Chinese pharmaceutical company, has announced that it...
Vertex Pharmaceuticals to Acquire Alpine Immune Sciences in a $4.9 Billion Deal
In a multibillion-dollar deal within the biotechnology sector, Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX), a leader...
Teva’s Ajovy Achieves Positive Results in Phase III Migraine Prevention Trial in China
Teva Pharmaceutical Industries Ltd (NYSE: TEVA), headquartered in Israel, has announced positive results from a...
LargeV Instrument’s IPO on STAR Board Halted Following Filing and Sponsorship Withdrawal
The initial public offering (IPO) of LargeV Instrument Corp., Ltd to the Shanghai Stock Exchange’s...
Enhertu Shows 58.3% Response Rate in Phase II Lung Cancer Study, AstraZeneca and Daiichi Sankyo Report
The Phase II DESTINY-Lung05 study results for Enhertu (trastuzumab deruxtecan), an antibody-drug conjugate co-developed by...
Yantai Dongcheng Secures Approval for Phase I Study of 68Ga-LNC1007 in Singapor
Yantai Dongcheng Pharmaceutical Group Co., Ltd. (SHE: 002675) has received approval from the Health Sciences...
Sino Biopharmaceutical to Present Phase II Data for Garsorasib at AACR 2024
Sino Biopharmaceutical Ltd. (HKG: 1177) announced that it will present the results of a Phase...
STRATA Skin Sciences Renews Exclusive Distribution Deals in China and Japan
STRATA Skin Sciences Inc. (NASDAQ: SSKN), a U.S.-based dermatology and plastic surgery firm, has announced...
Aptar Pharma Secures NMPA Approval for Airless Drug Delivery System in Chin
Aptar Pharma, a U.S.-based company, announced that its Mezzo+ CS (China Support) Airless dispensing solution...
BIO’s Chief Lobbyist Nick Shipley Resigns Amid Controversy Over WuXi AppTec
Nick Shipley, the chief lobbyist for the U.S.-based Biotechnology Innovation Organization (BIO), has resigned from...
Roche Secures CE Mark for Ventana HER2 Test, Enhancing Access to AstraZeneca’s Enhertu
Roche (SWX: ROG), based in Switzerland, has received CE marking from the European Commission (EC)...